Veradermics Incorporated (MANE)
NYSE: MANE · Pharmaceutical Preparations · New Haven, CT
Our rating: Cautious
Cautious reaffirmed at $156.56, low conviction, November 11, 2026.
Breaks if: The Cautious call would be wrong if Veradermics reports a first full quarter of product revenue exceeding $50 million within the next two quarterly prints, or receives an FDA approval paired with early evidence of commercial traction — either outcome would give the $6.5 billion valuation a plausible anchor and shift the picture toward Neutral. Conversely, if annual free-cash-flow burn widens beyond $150 million without a concurrent financing announcement, the thesis deepens rather than breaks.
Key figures
| Market value | $5.0B |
|---|---|
| Revenue, last 12 months | n/a |
| Net income, last 12 months | −$94M |
| Free cash flow, last 12 months | −$83M |
| Price to earnings | n/a |
| Free cash flow yield | −1.6% |
| Dividend yield | n/a |
| Operating margin | n/a |
| Return on equity | −26.7% |
| Beta to the S&P 500 | 1.17 |
| Volatility, annualized | 91.8% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | n/a | n/a | $-0.50 | −$23M |
| June 30, 2026 | n/a | n/a | $-0.58 | −$15M |
| March 31, 2026 | n/a | n/a | $-1.32 | −$21M |
| December 31, 2025 | n/a | n/a | $-37.70 | −$24M |
| September 30, 2025 | n/a | n/a | $-30.15 | −$19M |
| June 30, 2025 | n/a | n/a | $-24.19 | −$16M |
| March 31, 2025 | n/a | n/a | $-19.79 | −$13M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Diluted earnings per share are above zero: Claude 4%, Gemini 12%, Mistral 15%
- Free cash flow for the quarter is above zero: Claude 8%, Gemini 5%, Mistral 5%
30 ledger entries and 1 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.